Shares of Bank of Marin Bancorp (NASDAQ:BMRC) fell sharply during Monday's session after the company reported worse-than-expected quarterly earnings.
Bank of Marin reported quarterly earnings of 6 cents per share which missed the analyst consensus estimate of 18 cents per share. The company reported quarterly sales of $22.47 million which missed the analyst consensus estimate of $23.39 million, according to data from Benzinga Pro.
Bank of Marin Bancorp shares dipped 10.8% to $19.92 on Monday.
Here are some other stocks moving in today’s mid-day session.
Gainers
- 2U, Inc. (NASDAQ:TWOU) shares climbed 128% to $2.8535.
- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) shares climbed 117.8% to $0.9039 after the company announced it commenced its Phase 2a trial for LP-310 in Oral Lichen Planus.
- Planet Image International Limited (NASDAQ:YIBO) gained 61.6% to $4.75 after jumping around 56% on Friday.
- NLS Pharmaceutics AG (NASDAQ:NLSP) jumped 38% to $0.2644 after the company announced a merger in which Kadimastem will become a wholly owned subsidiary of NLS.
- Tivic Health Systems, Inc. (NASDAQ:TIVC) shares gained 37.8% to $0.6232 after gaining 11% on Friday.
- NIP Group Inc. (NASDAQ:NIPG) gained 34.4% to $12.25.
- Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) jumped 26.8% to $14.76.
- Renalytix Plc (NASDAQ:RNLX) jumped 24.2% to $0.4366.
- Meta Data Limited (NYSE:AIU) rose 23.5% to $2.9860.
- Venus Concept Inc. (NASDAQ:VERO) jumped 22.5% to $0.7936 after the company received a medical device license from Health Canada to market its Venus Bliss MAX system.
- Nuwellis, Inc. (NASDAQ:NUWE) gained 21.3% to $2.8862. Roth MKM analyst Jonathan Aschoff initiated coverage on Nuwellis with a Buy rating and announced a price target of $17.
- Longeveron Inc. (NASDAQ:LGVN) shares gained 19.8% to $4.1246 after the company disclosed study results from CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer’s disease.
- BurgerFi International, Inc. (NASDAQ:BFI) gained 19.3% to $0.5021. BurgerFi shares jumped 97% on Friday after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.
- Oil States International, Inc. (NYSE:OIS) climbed 18.8% to $5.63 after the company reported better-than-expected second-quarter financial results.
- PolyPid Ltd. (NASDAQ:PYPD) rose 18.4% to $4.19.
- Cepton, Inc. (NASDAQ:CPTN) jumped 18.4% to $2.9950 after the company announced it will be acquired by Koito for $3.17 per share in cash.
- CommScope Holding Company, Inc. (NASDAQ:COMM) rose 17.2% to $2.25 after reporting preliminary second quarter results.
- Serve Robotics Inc. (NASDAQ:SERV) gained 16.1% to $15.35.
- ON Semiconductor Corporation (NASDAQ:ON) jumped 13.7% to $79.76 after the company reported better-than-expected second quarter financial results.
- Koninklijke Philips N.V. (NYSE:PHG) rose 13.1% to $29.14 after the company reported better-than-expected second quarter earnings.
- Primega Group Holdings Limited (NASDAQ:PGHL) gained 9.5% to $5.09.
- ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) rose 8.5% to $18.48. ZIM Integrated Shipping Services will release its second quarter financial results on Monday, Aug. 19.
- Anavex Life Sciences Corp. (NASDAQ:AVXL) gained 6.4% to $7.18. Anavex Life Sciences presented comprehensive results from the Phase IIb/III study showing that blarcamesine, once daily orally, significantly slowed clinical decline in people with early Alzheimer’s disease.
- Tesla, Inc. (NASDAQ:TSLA) gained 5.6% to $232.15. Morgan Stanley analyst Adam Jonas reiterated Tesla with an Overweight and maintained a $310 price target.
Losers
- Cognition Therapeutics, Inc. (NASDAQ:CGTX) fell 34% to $1.5650 after the company reported Phase 2 results for Alzheimer’s drug.
- vTv Therapeutics Inc. (NASDAQ:VTVT) shares dipped 31.4% to $14.55 after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.
- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) shares fell 28.6% to $0.1830 after gaining 6% on Friday.
- Centuri Holdings, Inc. (NYSE:CTRI) fell 26.4% to $14.90 following downbeat quarterly results.
- Ventyx Biosciences, Inc. (NASDAQ:VTYX) dipped 24.4% to $2.23. The company released results from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn's disease, a type of inflammatory bowel disease that irritates and causes swelling in digestive tract.
- LuxUrban Hotels Inc. (NASDAQ:LUXH) shares fell 19.6% to $0.1536 after the company priced its $1.74 million public offering of 11,573,333 common shares at 15 cents per share.
- NuScale Power Corporation (NYSE:SMR) declined 18.5% to $8.84.
- Ocean Power Technologies, Inc. (NYSE:OPTT) fell 17.5% to $0.2544.
- Treasure Global Inc. (NASDAQ:TGL) shares fell 17% to $1.5243.
- Integra Resources Corp. (NYSE:ITRG) fell 16.6% to $0.8999. Integra Resources and Florida Canyon Gold entered into a definitive arrangement agreement, whereby Integra has agreed to acquire all of the issued and outstanding shares of FCGI pursuant to a court-approved plan of arrangement.
- Phio Pharmaceuticals Corp. (NASDAQ:PHIO) fell 16.6% to $3.3616. Phio Pharmaceuticals recently announced exercise of warrants for $3.1 million gross proceeds.
- Integra LifeSciences Holdings Corporation (NASDAQ:IART) dipped 13.9% to $27.05 after the company lowered its FY24 guidance below estimates.
- NANO Nuclear Energy Inc. (NASDAQ:NNE) fell 12.8% to $14.01.
- Coursera, Inc. (NYSE:COUR) fell 10.5% to $9.60.
- Sunnova Energy International Inc. (NYSE:NOVA) declined 10% to $7.24. Truist Securities analyst Jordan Levy maintained Sunnova Energy Intl with a Buy and raised the price target from $9 to $10.
- Mesoblast Limited (NASDAQ:MESO) fell 7.4% to $6.85. Mesoblast, last week, announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.
- Arm Holdings plc (NASDAQ:ARM) fell 6.3% to $139.61 after HSBC downgraded the stock from Hold to Reduce.
- Tandem Diabetes Care, Inc. (NASDAQ:TNDM) fell 6.3% to $37.53.
Now Read This: